English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Hyperinsulinemia, Diabetes type 2, and obesity have been identified as increased risk factors for a variety of cancers [1]. Conversely, insulin inhibition (INSINH) can plausibly limit cancer growth by demonstrated mechanisms including ketosis [2] and regulation of downstream signaling proteins such as mTOR (inhibition) and AMPK (amplification), already in development as drug targets [3,4]. Increased F-2-fluoro, 2-deoxyglucose (FDG) uptake on positron emission tomography (PET) scan is characteristic of many aggressive malignancies. We examined safety and feasibility of a four week INSINH diet in patients with advanced PET positive cancers, and compared exit vs. baseline PET scan changes as surrogate measures for tumor response.

A pilot safety-feasibility dietary trial targeting insulin inhibition in ten patients with advanced cancer